The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation
Open accessAbstract
In normal cells, p53 is maintained at a low level by ubiquitin-mediated proteolysis, but after genotoxic insult this process is inhibited and p53 levels rise dramatically. Ubiquitination of p53 requires the ubiquitin-activating enzyme Ubc5 as a ubiquitin conjugation enzyme and Mdm2, which acts as a ubiquitin protein ligase. In addition to the N-terminal region, which is required for interaction with Mdm2, the C-terminal domain of p53 modulates the susceptibility of p53 to Mdm2-mediated degradation. To analyze the role of the C-terminal domain in p53 ubiquitination, we have generated p53 molecules containing single and multiple lysine-to-arginine changes between residues 370 and 386. Although wild-type (WT) and mutant molecules show similar subcellular distributions, the mutants display a higher transcriptional activity than WT p53. Simultaneous mutation of lysine residues 370, 372, 373, 381, 382, and 386 to arginine residues (6KR p53 mutant) generates a p53 molecule with potent transcriptional activity that is resistant to Mdm2-induced degradation and is refractory to Mdm2-mediated ubiquitination. In contrast to WT p53, transcriptional activity directed by the 6KR p53 mutant fails to be negatively regulated by Mdm2. Those differences are also manifest in HeLa cells which express the human papillomavirus E6 protein, suggesting that p53 C-terminal lysine residues are also implicated in E6-AP-mediated ubiquitination. These data suggest that p53 C-terminal lysine residues are the main sites of ubiquitin ligation, which target p53 for proteasome-mediated degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Self-citationTumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063 · cited 2×
“One of the best-characterized functions of p53 is its transcriptional activity (26, 32). p53 increases the transcription of genes coding for important cell growth inhibitors, such as the p21Waf1/Cip1 gene (10), and apoptotic genes, such as that coding for Bax (42).”
BackgroundParticipation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 2×
“transcriptional activation domain (5, 43, 45).”
BackgroundActivation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Amino Acid Sequences Common to Rapidly Degraded Proteins: The PEST Hypothesis
Rogers, S., Wells, R., & Rechsteiner, M. (1986) · Science · doi:10.1126/science.2876518 · Cited by 2,537
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
CRM1 Is an Export Receptor for Leucine-Rich Nuclear Export Signals
Fornerod, M., Ohno, M., Yoshida, M., & Mattaj, I. W. (1997) · Cell · doi:10.1016/s0092-8674(00)80371-2 · Cited by 2,081
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
PEST sequences and regulation by proteolysis
Rechsteiner, M., & Rogers, S. W. (1996) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)10031-1 · Cited by 1,640
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
THE UBIQUITIN SYSTEM FOR PROTEIN DEGRADATION
Hershko, A., & Ciechanover, A. (1992) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.61.070192.003553 · Cited by 1,410
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · cited 1×
“The importance of this regulatory mechanism is illustrated by the fact that deletion of the mdm2 gene in mice induces an early embryonic lethality which is rescued by deletion of the p53 gene (24).”
BackgroundDNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204 · cited 2×
“Interestingly, lysine residue 382 becomes acetylated and lysine residue 386 is conjugated to SUMO-1 after cells are exposed to UV light (49, 55).”
BackgroundSUMO-1 Modification of IκBα Inhibits NF-κB Activation
Desterro, J. M. P., Rodriguez, M. S., & Hay, R. T. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80133-1 · Cited by 1,038
Self-citationNucleolar Arf sequesters Mdm2 and activates p53
Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., & Bar-Sagi, D. (1999) · Nature Cell Biology · doi:10.1038/8991 · Cited by 940
Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain
Treier, M., Staszewski, L. M., & Bohmann, D. (1994) · Cell · doi:10.1016/s0092-8674(94)90502-9 · Cited by 923
Regulation of the specific DNA binding function of p53
Hupp, T. R., Meek, D. W., Midgley, C. A., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 909
Self-citationUV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893
Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
Evidence for a Role of CRM1 in Signal-Mediated Nuclear Protein Export
Ossareh-Nazari, B., Bachelerie, F., & Dargemont, C. (1997) · Science · doi:10.1126/science.278.5335.141 · Cited by 717
Mapping of the p53 and mdm-2 interaction domains.
Chen, J., Marechal, V, & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689
In vivo ubiquitination and proteasome-mediated degradation of p53(1).
Maki, C. G., Huibregtse, J. M., & Howley, P. M. (1996) · PubMed · Cited by 645
SUMO-1 modification activates the transcriptional response of p53
Rodriguez, M. S., Desterro, J. M. P., Lain, S., Midgley, C. A., Lane, D. P., & Hay, R. T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.22.6455 · Cited by 639
Self-citationRoth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., & Levine, A. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.554 · Cited by 610
Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination.
Scherer, D. C., Brockman, J. A., Chen, Z., Maniatis, T., & Ballard, D. W. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11259 · Cited by 554
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.
Pavletich, N. P., Chambers, K. A., & Pabo, C. O. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2556 · Cited by 521
Nuclear Export Is Required for Degradation of Endogenous p53 by MDM2 and Human Papillomavirus E6
Freedman, D. A., & Levine, A. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.7288 · Cited by 518
Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1
Gostissa, M., Hengstermann, A., Fogal, V., Sandy, P., Schwarz, S. E., Scheffner, M., & Del Sal, G. (1999) · The EMBO Journal · doi:10.1093/emboj/18.22.6462 · Cited by 513
Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., & Rotter, V (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565 · Cited by 356
Zhang, Y., & Xiong, Y. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80351-2 · Cited by 348
Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins
Dang, C. V., & Lee, W. M. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84673-2 · Cited by 347
Midgley, C. A., Fisher, C. J., Bártek, J., Vojtések, B., Lane, D., & Barnes, D. M. (1992) · Journal of Cell Science · doi:10.1242/jcs.101.1.183 · Cited by 330
Self-citationp53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding
Midgley, C. A., & Lane, D. P. (1997) · Oncogene · doi:10.1038/sj.onc.1201459 · Cited by 311
Self-citationAllosteric activation of latent p53 tetramers
Hupp, T. R., & Lane, D. P. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00195-0 · Cited by 301
Self-citationNuclear Export Receptors: From Importin to Exportin
Ullman, K. S., Powers, M. A., & Forbes, D. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80361-x · Cited by 278
The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II.
Meek, D. W., Simon, S., Kikkawa, U., & Eckhart, W. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07524.x · Cited by 277
RB Regulates the Stability and the Apoptotic Function of p53 via MDM2
Hsieh, J.-K., Chan, F. S. G., O’Connor, D. J., Mittnacht, S., Zhong, S., & Lu, X. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80309-3 · Cited by 255
Midgley, C. A., Desterro, J. M., Saville, M. K., Howard, S., Sparks, A., Hay, R. T., & Lane, D. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203593 · Cited by 252
Self-citation(1997) · PubMed · Cited by 243
Mdm2 association with p53 targets its ubiquitination
Fuchs, S. Y., Adler, V., Buschmann, T., Wu, X., & Ronai, Z. (1998) · Oncogene · doi:10.1038/sj.onc.1202200 · Cited by 236
The specificity of the CRM1-Rev nuclear export signal interaction is mediated by RanGTP
Askjaer, P., Jensen, T. H., Nilsson, J., Englmeier, L., & Kjems, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33414 · Cited by 219
Regulation of Mdm2-Directed Degradation by the C Terminus of p53
Kubbutat, M. H. G., Ludwig, R. L., Ashcroft, M., & Vousden, K. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5690 · Cited by 193
Identification of novel mdm2 binding peptides by phage display.
Böttger, V., Böttger, A., Howard, S. F., Picksley, S. M., Chêne, P., Garcı́a-Echeverrı́a, C., Hochkeppel, H. K., & Lane, D. P. (1996) · PubMed · Cited by 182
Self-citationCritical Role for Lysines 21 and 22 in Signal-induced, Ubiquitin-mediated Proteolysis of IkB-α
Baldi, L., Brown, K., Franzoso, G., & Siebenlist, U. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.1.376 · Cited by 177
Laín, S., Midgley, C., Sparks, A., Lane, E. B., & Lane, D. P. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4433 · Cited by 149
Self-citationRolfe, M., Beer‐Romero, P., Glass, S., Eckstein, J., Berdo, I., Theodoras, A. M., Pagano, M., & Draetta, G. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3264 · Cited by 129
Ms, R., Wright, J., Thompson, J., Thomas, D., Baleux, F., Virelizier, J. L., Hay, R. T., & Arenzana‐Seisdedos, F. (1996) · PubMed · Cited by 121
Self-citationc-Abl Neutralizes the Inhibitory Effect of Mdm2 on p53
Sionov, R. V., Moallem, E., Berger, M., Kazaz, A., Gerlitz, O., Ben‐Neriah, Y., Oren, M., & Haupt, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8371 · Cited by 104
Rodríguez, M. S., Michalopoulos, I., Arenzana‐Seisdedos, F., & Hay, R. T. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2413 · Cited by 93
Self-citationDirect involvement of p53 in programmed cell death of oligodendrocytes.
Eizenberg, O., Faber‐Elman, A., Gottlieb, E., Oren, M., Rotter, V., & Schwartz, M. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07097.x · Cited by 87
Association of casein kinase II with immunopurified p53.
HERRMANN, C., Kraiss, S., & Montenarh, M. (1991) · PubMed · Cited by 82
Vojtěšek, B., Dolezalova, H., Lauerová, L., Svitáková, M., Havlis, P., Kovařík, J., Midgley, C. A., & Lane, D. P. (1995) · PubMed · Cited by 72
Self-citationIdentification of a Sequence Element from p53 That Signals for Mdm2-Targeted Degradation
Gu, J., Chen, D., Lichtenstein, J. H. R., Rubin, R. M., & Yuan, Z.-M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1243-1253.2000 · Cited by 71
Lane, D. P. (1998) · Nature · doi:10.1038/29166 · Cited by 63
Self-citationLiang, S., Hong, D., & Clarke, M. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.31.19817 · Cited by 59
The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
Mansur, C. P., Marcus, B., Dalal, S. N., & Androphy, E. J. (1995) · PubMed · Cited by 36
Cited by
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization
Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., & Gu, W. (2002) · Nature · doi:10.1038/nature737 · Cited by 1,031
Metadata
- Authors
- Rodriguez, M. S., Desterro, J. M. P., Lain, S., Lane, D. P., & Hay, R. T.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2000-11
- Volume
- 20
- Issue
- 22
- Pages
- 8458-8467
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2144919418
- Cited by
- 389
- References
- 64
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.